Dr Thompson, together with Louise Emmett and colleagues from UNSW, Garvan Institute, Kinghorn Cancer Centre and St Vincents/ St George Hospitals, are thrilled to have completed and published the results from the PRIMARY trial.
This is a world-first trial where PSMA-PET was compared to MRI and the combination of both, for detecting prostate cancer in men with raised PSA.
PSMA was a valuable addition to MRI, especially in men with equivocal or negative MRI (PIRADS 2-3) where the PSMA-PET was able to identify those men without cancer who could avoid biopsy.
Furthermore, the PSMA could identify those men with cancer and could allow targeting of the biopsy to the regions of cancer to avoid missing the cancer at the time of biopsy.
Dr Thompson, Prof Emmett and the multicentre research team are now designing a randomised controlled trial called ‘PRIMARY 2’, of PSMA +/- targeted biopsy vs conventional template biopsy in the setting of these men with PIRADS 2-3 suspected of Prostate cancer on PSA/ DRE.
https://twitter.com/drjamesethomps1/status/1436560270424375301?s=20
the full text of the article is available free for a limited time at the following link: